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Abstract
A wealth of evidence has now demonstrated that the microenvironment in which a tumorigenic cell evolves is as
critical to its evolution as the genetic mutations it accrues. However, there is still relatively little known about how
signals from the microenvironment contribute to the early events in the progression to malignancy. To address this
question, we used a premalignant mammary model to examine how fibroblasts, and the extracellular matrix (ECM)
proteins they secrete, influence progression to malignancy. Their effect on metastatic malignant cells was also
assessed for comparison. We found that carcinoma-associated fibroblasts, and the distinct aligned ECM they de-
posit, can cause both premalignant and malignant mammary epithelial cells to assume a mesenchymal morphology
that is associated with increased dissemination and metastasis, while benign reduction mammoplasty fibroblasts
favor the maintenance of an epithelial morphology and constrain early dissemination, tumor growth, and metastasis.
Our results suggest that normalizing the organization of the ECM could be effective in limiting systemic dissemination
and tumor growth.
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Introduction
It is now very well established that all the cells and extracellular
matrix (ECM) proteins within the microenvironment influence the
behavior of the epithelial cells they surround and play an important
role in the tumorigenic process [1]. However, there is still relatively
little known about how signals from the microenvironment con-
tribute to the early events in the progression to malignancy. In light
of the importance of early intervention in successfully treating malig-
nancies, and growing evidence that tumor cells can disseminate early
[2], there is a pressing need to better understand the early events
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involved in the tumorigenic process so as to identify new strategies
for prevention and for more effective therapeutic intervention.
Fibroblasts are among the most abundant cell type in the micro-
environment of solid tumors and are responsible for the elaboration
of a wide range of chemokines, growth factors, and ECM proteins
found therein, all of which contribute to the evolution of the tumor
[3]. The ECM is defined as a complex mixture of proteins (proteo-
glycans and adhesive glycoproteins such as collagens and laminins)
that provides structural support for organs and tissues. In addition,
the ECM plays an important role in the regulation of gene expres-
sion, growth factor activation, signal transduction, cell survival,
shape, and movement [4]. Carcinoma-associated fibroblasts (CAFs)
form a heterogeneous population, likely due to the diversity of
sources from which they have been postulated to arise [5–7] and
to the heterogeneity of the tumors in which they reside. The pivotal
role of fibroblasts and their associated ECM in cancer is highlighted
by the fact that an ECM signature alone can stratify primary breast
tumors into different subgroups with different clinical outcomes and
can also identify which patients within a “good prognosis” group (i.e.,
luminal) have a poorer outcome [8]. In addition, a stromal gene ex-
pression signature that includes alterations in the ECM and an “activated
fibroblast” phenotype has been reported to be a more powerful predic-
tor of prognosis than other prognostic signatures derived from whole
tumor samples [9].
These data suggest that targeting non-neoplastic components
within the microenvironment can lead to the development of new
therapies. Hence, to gain novel insights into how we could poten-
tially target the microenvironment therapeutically, and do so early
in the development of breast cancer, we examined how fibroblasts,
and the ECM proteins they secrete, influence the early events in
the development of breast cancer using a series of human mam-
mary epithelial cells (HMECs) isolated from disease-free reduction
mammoplasty tissues that display premalignant properties but are
not tumorigenic [10]. These include a subpopulation of HMEC in
which p16INK4A expression is repressed due to promoter methyla-
tion, which we refer to as vHMEC; vHMEC expressing oncogenic
Ha-rasV12, which we refer to as vHMEC-ras; and immortalized (but
non-tumorigenic) vHMEC expressing oncogenic Ha-rasV12, which
we refer to as vHMEC-ras0.5 [10]. We examined how fibroblasts
isolated from disease-free reduction mammoplasty tissues [reduction
mammoplasty fibroblasts (RMFs)] or cancer tissues (CAFs), and
their ECM, influence the behavior of these premalignant cells in
co-cultures in vitro as well as when co-injected in vivo. Their effect
on malignant cells was also assessed for comparison.
We found that CAFs, and the distinct aligned ECM they deposit,
caused both premalignant and malignant mammary epithelial cells
to assume a mesenchymal morphology that was associated with in-
creased dissemination and metastasis. In contrast, RMFs favored the
maintenance of an epithelial morphology and constrained tumor
growth and metastasis. Our results suggest that normalizing the
organization of the ECM could be effective in limiting early dis-
semination and tumor growth.
Materials and Methods
Co-culture Assays
Epithelial cells were seeded at a concentration of 1 × 105 cells/well
into six-well plates. Twenty-four hours later, cells were washed with
serum-free growth medium and stained with the CellTracker Green
5-chloromethylfluorescein diacetate (CMFDA) probe (Life Technol-
ogies, Grand Island, NY) for 30 minutes at 37°C. The cells were then
washed twice with complete growth medium and allowed to recover
for 2 to 3 hours in this medium. The medium was then aspirated,
and 3 × 105 fibroblasts resuspended in 3 ml of mammary epithelial cell
growth medium (MEGM) + 0.5% FBS (for primary HMEC cultures)
or 3 ml of Dulbecco’s modified Eagle’s medium + 10% FBS (for
MDA-MB-231 cells) were seeded onto the CMFDA-stained epithelial
cultures. Co-cultures were incubated for 3 to 4 days, cell morphology
was assessed, and representative images were captured at 10× magnifi-
cation with a Nikon DS-Qi1Mc monochrome camera mounted on
a Nikon Eclipse TE300 microscope. The cells were then harvested
and the CMFDA-positive epithelial cell population was recovered by
fluorescence-activated cell sorting (FACS) for further analysis.
Matrix Overlay Assays
Fibroblasts were seeded onto collagen-coated six-well plates in com-
plete growth medium (RPMI + 10% FBS) at 1.2 × 105 cells/well. Three
to four days later, fibroblasts were removed by gently washing the cells
twice with a freshly prepared solution of 20 mM NH4OH diluted in
sterile water. The denuded matrix was examined microscopically to
ensure complete removal of the fibroblasts, gently washed twice with
sterile water, and stained with picrosirius (0.1% sirius red diluted in
saturated picric acid) overnight at room temperature to better visualize
the matrix. The next day, the staining solution was removed by wash-
ing three times with water, and representative images were captured
at 10× magnification with a Nikon DS-Qi1Mc monochrome camera
mounted on a Nikon Eclipse TE300 microscope. Replicate unstained
wells were used to assess the effect of the denuded matrix on epithelial
cells. For these experiments, epithelial cells were seeded on top of the
denuded matrix deposited by the fibroblasts at 1 × 105 cells/well in 3 ml
of complete growth medium. Two to three days later, cell morphology
was assessed, and representative 10× images were captured as above.
Thy-1 and Epithelial Cell Adhesion Molecule Staining
Cells were trypsinized, washed once in phosphate-buffered saline
(PBS) + 2% FBS, and incubated in MEGM + 2% FBS for 1 hour at
37°C with gentle rocking. The cells were then washed once in wash solu-
tion (PBS + 1% BSA) and incubated in 100 μl of wash solution contain-
ing allophycocyanin (APC)-conjugated anti–Thy-1 (1 μl per 1 × 106 cells;
BD Pharmingen Cat. No. 559869) or fluorescein isothiocyanate–
conjugated anti–epithelial cell adhesion molecule (EpCAM; 1 μl per
1 × 106 cells; Biomeda Cat. No. FM010) antibodies for 30 minutes
at room temperature with shaking. Following staining, cells were
washed twice with wash solution and once with PBS. Cells were then
fixed in PBS + 1% paraformaldehyde and analyzed for Thy-1 or
EpCAM expression with a FACSCalibur. Flow cytometry files were
analyzed with the FlowJo (v8.8.02) software.
Immunoblot Analysis
Protein extracts were separated by sodium dodecyl sulfate–
polyacrylamide gel electrophoresis, transferred onto polyvinylidene fluo-
ride (PVDF) membranes, and probed using standard procedures.
Mouse monoclonal antibodies against E-cadherin (#610181), N-cadherin
(#610920), and fibronectin (Fn; #610077) were obtained from BD Bio-
sciences (San Jose, CA). The mouse monoclonal antibody against β-actin
(#5441) was obtained from Sigma-Aldrich (St Louis, MO). The rabbit
250 ECM Structure Affects Tumorigenesis and Metastasis Dumont et al. Neoplasia Vol. 15, No. 3, 2013
polyclonal antibodies against the phosphorylated form of Smad2
(#3101), Erk1/2 (#9101), Jun (#9261), and p38 mitogen-activated
protein kinase (MAPK; #9211) were obtained fromCell Signaling Tech-
nology (Danvers, MA), while those against lysyl oxidase (LOX;
#NB100-2527), tenascin C (TNC; #19101) and biglycan (#54855)
were fromNovus (Littleton, CO), Chemicon (Billerica,MA), andAbcam
(Cambridge, MA), respectively.
In Vivo Premalignant and Malignant Tumor Studies
For the in vivo studies with premalignant cells, the vHMEC-ras0.5
cells were engineered to express luciferase (Lux) using a lentiviral vector
from System Biosciences (Mountain View, CA) encoding green fluo-
rescent protein (GFP) and firefly Lux (pGF-CMV-EF1-Neo). In some
experiments (designed to mirror in vitro co-cultures), ras0.5-GFPLux
cells were injected orthotopically into the right and left No. 4 mam-
mary fat pads of 6- to 8-week-old female severe combined immuno-
deficiency (SCID)-Beige mice either alone (1 × 106 cells per gland) or in
combination with 3 × 106 fibroblasts. In other experiments (designed
to mirror in vitromatrix overlay assays), the mammary glands of 3-week-
old NOD/SCID mice were cleared of their endogenous epithelium
and injected with 2.5 × 105 RMFs or CAFs at a 1:1 ratio with hTERT-
immortalized RMFs, as described by Proia and Kuperwasser [11]. The
fibroblasts were allowed to deposit matrix on their own in vivo for 2 to
3 weeks before the injection of 2.5 × 106 ras0.5-GFPLux cells. Cell sur-
vival was monitored biweekly by bioluminescence imaging using the
Xenogen IVIS Imaging System (Caliper Life Sciences, Hopkinton,
MA). Quantification of photon emission from the bioluminescent signal
was performed using the acquisition and analysis software Living Image
(Xenogen). By 3 to 5 weeks, the ras0.5-GFPLux cells could no longer be
detected by imaging in the majority of the mice. Hence, experiments
were terminated, blood was collected to quantify the number of circulat-
ing ras0.5-GFPLux cells, and mammary glands were harvested for histo-
logic analysis and staining.
For the tumor studies, the malignant MDA-MB-231 breast cancer
cells were engineered to express Lux (231-Lux) using the pLLRN
retroviral Lux vector in Clontech’s Pantropic Retroviral Expression
System, according to the manufacturer’s instructions. The 231-Lux
cells were injected directly into the surgically exposed right and left
No. 4 mammary fat pads of 6- to 8-week-old female SCID-Beige mice
either alone (5 × 105 cells per gland) or in combination with 1.5 × 106
fibroblasts. Cell growth and survival were monitored and quantified
weekly by bioluminescence imaging as described above. In addition,
mammary glands were palpated weekly after cell injection for the presence
of tumors. Tumor latency was recorded when palpable tumors > 15mm3
were detected. Tumor lengths and widths were measured weekly with
calipers and corresponding tumor volumes were calculated using the
formula [volume = (width)2 × length/2]. Eight weeks following injec-
tion of cells, mice were anesthetized with avertin, blood was collected
to measure circulating tumor cells (CTCs), and the lungs (along with
other organs for comparison) were harvested and imaged ex vivo to
document and quantify metastases based on the presence of lumines-
cence in each lung. Tumors were weighed, measured with calipers to
calculate final tumor volume, and cut in half. Half of each tumor was
snap frozen in liquid nitrogen for subsequent analysis, while the other
half of the tumor along with all the organs were fixed and processed for
histologic examination and staining. All experiments involving ani-
mals were conducted in compliance with the Institutional Animal
Care and Use Committee guidelines and were approved by the Insti-
tutional Animal Care and Use Committee Ethics Committee.
Quantification of CTCs
Blood was collected through cardiac puncture using a 25-G 5/
8 needle attached to a 1-ml syringe precoated with acid citrate
dextrose and transferred to 2.0-ml K2EDTA vacutainer tubes (BD
Biosciences). Blood was stored at room temperature overnight. The
next day, genomic DNA was extracted from the blood using Promega’s
Wizard Genomic DNA Purification Kit according to the manufac-
turer’s instructions. The DNA was quantified and diluted to 10 ng/μl
for each sample. The levels of EpCAM DNA in each sample were
quantified by quantitative polymerase chain reaction (qPCR) using
a custom-designed, human-specific, EpCAM primer-reporter set
(Applied Biosystems, Inc, Foster City, CA). The forward and reverse
primer sequences for EpCAM were 5′-GCAGGAGAATTGCCTGA-
ATCC-3′ and 5′-GAGTGCAATGGCATCATCTCA-3′, respectively.
The reporter sequence was 5′-FAM-CAACCTCCGCCTCCC-FAM-3′.
Quantification of EpCAM DNA levels was used as a surrogate for the
number of CTCs in the blood. This method was validated by spiking
in increasing numbers of human 231-Lux cells into naïve blood
samples, as shown in Figure W1. Similar results were obtained with
a custom-designed firefly Lux primer-reporter set (Applied Biosystems).
The forward and reverse primer sequences for Lux were 5′-GTA-
CACGTTCGTCACATCTCATCTA-3′ and 5′-CACGATCAAAG-
GACTCTGGTACAAA-3′, respectively. The reporter sequence was
5′-FAM-CCTCCCGGTTTTAATG-FAM-3′.
Real-Time qPCR
Total RNA was isolated from cells and cDNA synthesized using
standard methods. qPCR (Taqman) was performed on cDNA using
the standard curve method with primer/probe sets (Applied Bio-
systems) for stromal-derived factor-1 (SDF-1; Hs00171022_m1).
The expression of glucuronidase B (Integrated DNA Technologies,
Inc, Coralville, IA) was used to normalize for variances in input cDNA.
The forward and reverse primer sequences for glucuronidase B were
5′-CTCATTTGGAATTTTGCCGATT-3′ and 5′-CCGAGGAAG-
ATCCCCTTTTTA-3′, respectively. The reporter sequence was
5′-FAM-TGAACAGTCACCGACGAGAGTGCTGGTA-TAM-3′.
Each experiment was performed at least in triplicate. Error bars repre-
sent the standard error of the mean in a representative experiment.
Quantification of Immunohistochemical Stains
For quantification of Ki67 and cleaved caspase 3 (CC3) stains, three
to four representative 20× images from each section were captured and
the number of positive nuclei were quantified using the inForm Ad-
vanced Image Analysis Software (Caliper Life Sciences). Quantification
of ECM alignment was carried out through automated image analy-
sis, using a regularity index designed to capture oriented ECM fiber
bundles in each sample. Differential analysis between different treat-
ment groups was performed as described in Quantification of Regular-
ity Index section (Figures W2–W4).
Results
Mammary Epithelial Cells Acquire a Mesenchymal
Morphology When Co-cultured with CAFs but Not RMFs
To examine how signals from the microenvironment influence the
behavior of epithelial cells early in breast cancer development, vHMEC,
vHMEC-ras, and vHMEC-ras0.5 cells were co-cultured with RMFs
or CAFs. In this assay, the epithelial cells were stained with a green
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tracker dye before the addition of fibroblasts so that they could be
readily distinguished from the fibroblast population in the co-cultures.
As shown in Figure 1A, all three epithelial cell populations maintained
their epithelial morphology when co-cultured with RMFs. However,
when co-cultured with CAFs, the vHMEC-ras0.5 cells assumed a
mesenchymal morphology while the vHMEC and vHMEC-ras cells
did not. We have previously shown that vHMEC-ras0.5 cells exhibit
greater cellular plasticity and accumulate more epigenomic alterations
than the vHMEC and vHMEC-ras populations [10,12], suggesting
that multiple alterations may be required to render mammary epithelial
cells responsive to environmental cues that promote a mesenchymal
phenotype. In light of the responsiveness of vHMEC-ras0.5 cells to
CAFs, we used these cells as a premalignant model for subsequent
experiments in our studies.
The transition from an epithelial to a mesenchymal morphology is
often associated with up-regulation of mesenchymal markers and
down-regulation of epithelial markers. Hence, we examined the expres-
sion of the mesenchymal markers Fn and N-cadherin, and the epithelial
marker E-cadherin, by immunoblot analysis in vHMEC-ras0.5 cells
following co-culture with the different fibroblasts. As indicated in
Figure 1B, induction of the mesenchymal morphology was associated
with a differential up-regulation in the expression of Fn and N-cadherin
but no change in the expression of E-cadherin, suggesting that the
cells were not undergoing a full epithelial-to-mesenchymal transition.
To assess the induction of the mesenchymal phenotype more quan-
titatively, we examined the expression of two additional cell surface
markers that could be readily quantified by flow cytometry, the mesen-
chymal marker Thy-1 and the epithelial marker EpCAM. In these
experiments, we observed an increase in the percentage of vHMEC-
ras0.5 cells expressing Thy-1 and a corresponding decrease in the per-
centage of cells expressing EpCAM following co-culture with CAFs
relative to RMFs (Figure 1C ).
We then screened RMFs isolated from 8 different individuals and
CAFs isolated from 15 different individuals in co-cultures with vHMEC-
ras0.5. Of the 8 RMFs examined, only one induced the mesenchymal
phenotype, while of the 15 CAFs examined, 12 did. The induction of
the mesenchymal phenotype did not correlate with the proliferation rate
of the fibroblasts but did correlate with the induction of Thy-1 expression
Figure 1. Premalignant mammary epithelial cells acquire a mesenchymal morphology when co-cultured with CAFs but not RMFs. (A) Rep-
resentative 10× images of epithelial cells co-cultured with RMFs or CAFs for 3 days. (B) Immunoblot analysis of Fn, N-cadherin (N-cad),
and E-cadherin (E-cad) in lysates of vHMEC-ras0.5 cells isolated by FACS after they had been cultured either alone, with RMFs, or with CAFs
for 3 days. Representative immunoblots are shown. (C) Flow cytometric analysis of Thy-1 and EpCAM expression in vHMEC-ras0.5 cells
cultured as above in B. Bar graphs represent the averages ± SEM of multiple experiments combined. For Thy-1: alone (n = 12), RMF146
(n = 6), CAF1363 (n = 11). For EpCAM: alone (n = 3), RMF146 (n = 3), CAF1363 (n = 2). Student’s t test for Thy-1: alone versus RMF146
(P < .001), alone versus CAF1363 (P < .001); for EpCAM: alone versus RMF146 (P = .17), alone versus CAF1363 (P = .02). Statistically
significant differences in expression between cells in co-culture and the cells alone are denoted with asterisk.
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in the vHMEC-ras0.5 cells. As summarized in Table 1, it was induced in
less than 15%of vHMEC-ras0.5 cells when the cells were co-culturedwith
fibroblasts that failed to induce the mesenchymal phenotype and in more
than 20% of vHMEC-ras0.5 cells when they were co-cultured with fibro-
blasts that did. Hence, the induction of Thy-1 expression was used as a
non-subjective surrogate for the induction of themesenchymal phenotype.
On the basis of this metric and an assessment of cell morphology, a sub-
set of RMFs and CAFs with varying abilities to induce the mesenchymal
phenotype was selected for further study.
The ECM Deposited by CAFs Differs from that Deposited by
RMFs and Contributes to the CAF-Induced Mesenchymal
Phenotype Observed in Epithelial Cells
Next, we examined whether the CAF-induced mesenchymal
phenotype could also be induced by CAF-conditioned media, CAF
co-culture–conditionedmedia, or byCAFs in transwell co-cultures with
vHMEC-ras0.5 cells where the two cell populations were not in direct
contact with one another. Interestingly, the mesenchymal phenotype
was not induced in the epithelial cells under any of those conditions,
suggesting that it was not due to a factor secreted in the medium (data
not shown). In light of these data, and of the fact that the epithelial cells
co-cultured with CAFs appeared very elongated and regularly arranged
in a parallel pattern, as though they were lining up on tracks, we exam-
ined whether the mesenchymal morphology induced in the presence
of CAFs could be due to differences in the organization of the ECM
deposited by the different fibroblasts. Picrosirius staining of the ECM
deposited by fibroblasts revealed that, unlike the ECM deposited by
the RMFs, which exhibited a random mesh-like appearance, the
ECM deposited by CAFs was remarkably aligned in a parallel pattern
(Figure 2A), as it has been reported to appear both in vitro [13,14]
and in regions adjacent to invasive tumors in vivo [15,16]. In addi-
tion, when epithelial cells were seeded on top of the ECM deposited
by CAFs (after removal of the fibroblasts), they assumed a mesenchymal
morphology similar to that observed when co-cultured with CAFs
(Figure 2A), and the percentage of epithelial cells expressing Thy-1 in-
creased correspondingly (Figure 2B). These data suggest that the
mesenchymal morphology assumed by epithelial cells co-cultured with
CAFs is governed at least in part by the organization of the ECM that
the CAFs deposit. If this is true, we reasoned that disrupting collagen
deposition by co-culturing the cells in the presence of collagenase would
inhibit the CAF-induced mesenchymal morphology. Indeed, both the
CAF-induced mesenchymal phenotype and the CAF-induced increase
in Thy-1 expression were blocked when the cells were co-cultured in the
presence of collagenase. Under these conditions, the cells maintained
their epithelial morphology or appeared live but rounded (Figure 2, C
andD). In addition, when epithelial cells, which had acquired a mesen-
chymal morphology in the presence of CAFs, were isolated by FACS
and replated in the absence of CAFs, they reverted back to their epithe-
lial morphology, indicating that continued exposure to the CAFs, or the
ECM they deposit, is required for maintenance of the mesenchymal
phenotype (Figure W5).
Transforming Growth Factor–β, Erk, Jun, and Rho Signaling
Are Required for the CAF-Induced Mesenchymal Phenotype
To gain insight into the mechanism by which CAFs induce the mes-
enchymal phenotype in epithelial cells, we examined what signaling
pathways were activated in the epithelial cells after they had been co-
cultured with RMFs or CAFs for 3 to 4 days. For these experiments,
epithelial cells were isolated from co-cultures by FACS, and the phos-
phorylation status of candidate signaling proteins within the epithelial
Table 1. Description of Fibroblasts Screened in Co-culture Assay.
Cell Name Mes %Thy-1+ Population Doubling Time (Days) Age History and Diagnosis ER PR HER2
RMF9 − 13.7 6.7 35
RMF13 − 11.9 8.3 33
RMF48 − 14.2 5.3 16
RMF146 − 13.4 ± 1.5 5 46
RMF146-Mes +/− 19.3 ± 0.9 46
RMF151 − 13.9 6.3 44
RMF156 − 12.4 ± 2.5 5.3 47
RMF163 − 12.4 ± 2.3 4.1 17
RMF166 − 7.8 7.1 39 Prophylactic mastectomy
Total 1/8
CAF20 + 38.7 ± 9.5 12.5 53 IDC + + 1+
CAF25 + 31.2 3.5 57 IDC + + 1+
CAF26 + 24.4 ± 4.6 26 Invasive micropapillary CA + + +
CAF29 +/− 9.1 49 IDC + +
CAF100 − 9.9 38 IDC − − 3+
CAF126 + 11.1 67 IDC, grade II with DCIS + + −
CAF149 +/− 52 IDC with DCIS − − −
CAF150 − 8.7 3.4 52
CAF201 +/− 51 IDC with DCIS − − −
CAF304 − 5.6 73 IDC, grade III, 1.7 cm with DCIS − − −
CAF559 + 19.5 ± 1.7 4.4 IDC
CAF910 + 12.5
CAF966 + 5.9 60 IDC
CAF1363 + 52.0 ± 4.5 4.4 63 Mucinous CA, grade II, 3.4 cm, DCIS, grade III, 0.6 cm + + 2+
CAF1366 +/− 4.3 61 IDC grade II, 1.5 cm with LVI 3+ 3+ −
Total 12/15
ER indicates estrogen receptor; PR, progesterone receptor; LVI, lymphovascular invasion.
Description of fibroblasts screened in co-culture assays with vHMEC-ras0.5 cells detailing a qualitative assessment of whether or not they induced the mesenchymal phenotype (abbreviated as Mes),
where (+) refers to induction, (+/−) refers to partial induction, and (−) refers to no induction, as well as a quantitative assessment of whether they induced the mesenchymal phenotype based on the
induction of the mesenchymal marker Thy-1 indicating that the percentage of Thy-1–positive cells is less than 15% following co-culture with fibroblasts that fail to induce the mesenchymal phenotype
and greater than 20% following co-culture with fibroblasts that induce the mesenchymal phenotype. Population doubling times were calculated from the growth curves of each fibroblast over several
passages and indicate that induction of the mesenchymal phenotype does not correlate with proliferation rate. Where blank, values were not calculated or patient data were not available.
Neoplasia Vol. 15, No. 3, 2013 ECM Structure Affects Tumorigenesis and Metastasis Dumont et al. 253
cells was assessed by immunoblot analysis. Since transforming growth
factor–β (TGFβ) plays a critical role in modulating cellular plasticity
and in regulating ECM deposition, we examined whether the signaling
pathways that have been implicated in these TGFβ-mediated functions
[17–20] were differentially activated in vHMEC-ras0.5 cells following
co-culture with CAFs. As shown in Figure 3A, a differential increase
in the phosphorylation of Smad2, Erk1/2, and Jun was observed in
vHMEC-ras0.5 cells co-cultured with CAFs relative to RMFs, while
p38 phosphorylation remained unchanged. To determine whether
the up-regulation in Smad, Erk1/2, and Jun signaling was required
for the CAF-induced mesenchymal phenotype, vHMEC-ras0.5 cells
were co-cultured with CAFs in the presence of chemical inhibitors that
block each pathway. Blockade of the Smad, Erk1/2, and Jun signaling
pathways, whose activity was increased by CAFs, with TGFβ receptor
kinase inhibitor (TβRki), MEK inhibitor, and JNK inhibitor, respec-
tively, inhibited the CAF-induced mesenchymal phenotype, while
blockade of the p38 MAPK pathway, which was not differentially in-
duced by CAFs, did not (Figure 3B). Inhibition of the CAF-induced
mesenchymal phenotype was associated with a decrease in the expres-
sion of the mesenchymal marker Thy-1 (Figure W6). These data in-
dicate that the up-regulation of the Smad, Erk1/2, and Jun signaling
pathways in the vHMEC-ras0.5 cells exposed to CAFs is necessary
for the acquisition of the mesenchymal phenotype.
Since Rho-associated kinase (ROCK) signaling plays a fundamental
role in regulating cell morphology, adhesion, and motility [21,22], we
also investigated whether blockade of ROCK signaling could inhibit
the CAF-induced mesenchymal phenotype. Indeed, it did (consistent
with its important role in cytoskeletal reorganization), while blockade of
the phosphatidylinositol 3-kinase (PI3K) pathway with either LY294002
(PI3K inhibitor) or rapamycin mammalian target of rapamycin inhib-
itor (mTORi) did not (Figure 3B). The fact that not all of the signal-
ing pathways examined affected the acquisition of the mesenchymal
morphology points to the contribution of specific signaling pathways.
CAFs Promote the Dissemination of Premalignant
Cells In Vivo
The acquisition of a mesenchymal phenotype is often associated
with increased motility. In addition, studies have shown that tumor
Figure 2. The CAF-induced mesenchymal phenotype is due to differences in the organization of the ECM deposited by CAFs. (A) Repre-
sentative 10× images of ECM stainedwith picrosirius 4 days after seeding and removal of fibroblasts (top panels) and of vHMEC-ras0.5 cells
overlaid on top of ECM (bottom panels). (B) Flow cytometric analysis of Thy-1 expression in vHMEC-ras0.5 cells overlaid on control ECM
(no fibroblasts seeded) or ECM deposited by RMFs or CAFs for 2 days. Analysis of one representative experiment is shown. Inset shows
percentage of Thy-1+ cells based on no antibody control for histogram shown. (C) Representative 10× images of vHMEC-ras0.5 cells
co-cultured with RMFs or CAFs for 3 days in the absence or presence of collagenase. (D) Flow cytometric analysis of Thy-1 expression
in the CMFDA-labeled vHMEC-ras0.5 cells of the experiment shown in C; top row, no collagenase; bottom row, + collagenase. Analysis
of one representative experiment is shown.
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cells can move on collagen fibers and use these fibers as tramlines to
rapidly move through the stroma away from the tumor mass [23].
Hence, we reasoned that if the mesenchymal phenotype we were
observing in vitro was biologically relevant in vivo, the aligned ECM
deposited by CAFs might promote the dissemination of vHMEC-
ras0.5 cells in vivo. To test this hypothesis, vHMEC-ras0.5 cells were
genetically engineered to express GFP-Lux (ras0.5-GFPLux) to allow
their direct visualization by bioluminescence imaging in vivo. The cells
were injected either alone or in combination with RMFs or CAFs into
the number four mammary glands of immunocompromised mice.
Three weeks following injection, the ECM content in their mammary
glands was assessed by picrosirius staining to determine whether the
aligned ECM deposited by CAFs in vitro could also be observed
in vivo. In addition, blood was collected and the number of circulat-
ing ras0.5-GFPLux cells was quantified by qPCR by measuring
the levels of human EpCAM in genomic DNA extracted from the
blood.
As shown in Figures 4A and W7, the ras0.5-GFPLux cells injected
into the mammary glands could be detected both by bioluminescence
imaging and histologically (Figure 4A, first and second rows). The
histologic detection of these human cells in the mouse mammary
gland was confirmed using a human-specific lamin A/C stain (Fig-
ure 4A, third row). Assessment of the ECM by picrosirius staining re-
vealed that the ECM deposited in the presence of CAFs was not only
more abundant but also more aligned than that observed in the pres-
ence of RMFs or when the cells were injected alone [Figures 4, A
(fourth row) and B, and W7]. These data suggest that the aligned
ECM deposited by the CAFs in vitro can also be detected in vivo
and could thus potentially be used as tracks to disseminate. Indeed,
co-injection with CAFs caused a 15% increase in the number of cir-
culating ras0.5-GFPLux cells, while co-injection with RMFs caused
a 38% decrease in the number of circulating ras0.5-GFPLux cells rela-
tive to the cells injected alone (Figure 4C). An even greater differen-
tial increase in dissemination in the presence of CAFs relative to RMFs
(2.4-fold) was observed when fibroblasts were injected into the cleared
mammary fat pads of mice before injection of the ras0.5-GFPLux cells
(to mimic our in vitro matrix overlay experiments; Figure 4D).
To determine whether a CAF’s ability to promote dissemination
correlated with its ability to induce the aligned mesenchymal pheno-
type, we examined whether a CAF (CAF304) that failed to induce
the mesenchymal phenotype in co-cultures with ras0.5-GFPLux cells
could enhance dissemination. For these experiments, ras0.5-GFPLux
cells were injected orthotopically either alone or in combination with
CAF304, and blood was collected 2 and 5 weeks following injection of
the cells. No difference in the number of circulating ras0.5-GFPLux
cells was detected between the two groups at either time point (Fig-
ure W8), suggesting that dissemination correlates with the induction
of the aligned mesenchymal phenotype and that the behavior of CAFs
in vitro is biologically relevant in vivo.
RMFs Suppress, while CAFs Promote, the Tumorigenic and
Metastatic Potential of Malignant Cells In Vivo
Having observed that RMFs could suppress, and CAFs could pro-
mote, the dissemination of premalignant cells in vivo, we examined
whether they could similarly alter the tumorigenic and metastatic po-
tential of malignant cells in vivo. To address this question, we chose
to use the metastatic MDA-MB-231 breast cancer cells as a malignant
model. Although these cells lack E-cadherin expression and are already
somewhat mesenchymal, they became elongated and aligned in a
parallel pattern as though they were lining up on tracks when they
were co-cultured with CAFs (just like the vHMEC-ras0.5 cells did;
see Figure W9). Hence, we reasoned that if the MDA-MB-231 cells
could use the aligned ECM deposited by CAFs as tramlines to dis-
seminate, their metastatic potential could be enhanced. To test this,
we engineered the MDA-MB-231 cells to express Lux (231-Lux) so
that their behavior could be monitored by live bioluminescence imag-
ing. The 231-Lux cells were then injected orthotopically either alone
or in combination with RMFs isolated from four different individuals
or CAFs isolated from three different individuals. All but 2 of the
131 mice injected developed tumors and did so with a latency of
Figure 3. The CAF-induced mesenchymal phenotype is dependent on the activation of the Smad, Erk, Jun, and Rho signaling pathways.
(A) Representative immunoblots of signaling proteins expressed in vHMEC-ras0.5 cells after they were cultured either alone (lane 1)
or with RMFs (lane 2) or CAFs (lane 3) for 3 days. (B) Representative 10× images of vHMEC-ras0.5 cells co-cultured with CAFs in the
absence or presence of different pathway kinase inhibitors, as indicated: TβRKi (LY364947, 10 μM), MEK inhibitor (U0126, 10 μM), JNK
inhibitor II (10 μM), p38MAPKi (SB203580, 10 μM), PI3K inhibitor (LY294002, 10 μM), mTORi (rapamycin, 10 nM), and ROCK inhibitor
(Y27632, 40 μM).
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∼3 to 4 weeks (Table 2). Hence, the fibroblasts did not have much of
an effect on tumor incidence or latency. However, all four RMFs sig-
nificantly inhibited primary tumor growth (Figure 5A) resulting in an
approximate 30% to 50% decrease in final tumor volume and weight
(Figure 5B). In contrast, each CAF had a different effect on primary
tumor growth (Figure 5A). Specifically, CAF1366 had little or no effect
on final tumor volume, yet it caused a small (15%) but statistically sig-
nificant (P = .02) increase in final tumor weight (Figure 5B). CAF559
caused an ∼30% increase, while CAF1363 caused an ∼30% decrease,
in final tumor volume and weight (Figure 5B).
In a previous study where CAFs were injected in combination with the
MCF7-ras breast cancer cell line, all CAFs examined stimulated tumor
growth and did so through their ability to secrete SDF-1 [24]. Hence,
we examined the expression of SDF-1 in our fibroblasts and found that
it was expressed at low levels in all the fibroblasts except in CAF559,
which was the only CAF that stimulated the growth of 231-Lux cells
in our experiments (Figure W10). Hence, our results are in agreement
with previous reports and, in addition, highlight the fact that there is con-
siderable heterogeneity between CAFs, consistent with the intratumoral
and intertumoral heterogeneity observed in human breast cancer [25].
Figure 4. CAFs deposit aligned matrix and promote the dissemination of premalignant cells in vivo. (A) Bioluminescence imaging, hema-
toxylin and eosin (H&E), lamin A/C, and picrosirius staining of mammary glands harvested 3 weeks following orthotopic injection of 1 ×
106 ras0.5-GFPLux alone or in combination with 3 × 106 fibroblasts. All images were captured at 10× (higher 40× magnification images
are available in FigureW7). The location of ras0.5-GFPLux cells is indicated by arrows in the H&E and outlined with a white dashed line in the
picrosirius image. (B) Bar graphs represent the averages ± SEM of mammary ECM abundance and alignment obtained through automated
image analysis (alone, n = 18; RMF163, n = 14; CAF559, n = 18). Student’s t test comparing ECM abundance: alone versus RMF163 (P=
.4), alone versus CAF559 (P < .001), RMF163 versus CAF559 (P = .03); comparing ECM alignment: alone versus RMF163 (P = .4), alone
versus CAF559 (P < .001), RMF163 versus CAF559 (P < .001). (C and D) qPCR analysis of EpCAM levels in genomic DNA extracted from
blood collected 3 weeks following: (C) injection of 1 × 106 ras0.5-GFPLux cells alone (n=4), or in combinationwith 3× 106 RMF163 (n=4),
or 3 × 106 CAF559 (n = 8). Student’s t test comparing qPCR replicates from alone versus RMF163 (P = .04), alone versus CAF559 (P = .4),
RMF163 versus CAF559 (P= .003); and (D) injection of 2.5 × 106 ras0.5-GFPLux cells into RMF163 (n= 4) or CAF559 (n= 4) pre-injected fat
pads. Student’s t test comparing qPCR replicate values of nanogram EpCAM per milliliter of blood collected frommice in the RMF163 group
versus CAF559 group (P = .03). Statistically significant differences between groups are denoted with asterisk.
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Because 231-Lux cells metastasize predominantly to the lung, to
assess the impact of the fibroblasts on metastatic potential, lungs
were harvested 8 weeks following injection of the tumor cells and
imaged ex vivo to accurately quantify total metastatic burden by bio-
luminescence. In addition, surface lung metastases were counted
using a dissection scope (Figure W11). Although the number of mice
that developed lung metastases was similar between groups, the num-
ber of metastases per lung differed. As shown in Figure 6A, and
summarized in Table 3, two of the four RMFs (RMF163 and
RMF9) significantly decreased the number of surface metastases per
lung, while all three CAFs increased the number of surface metas-
tases per lung. Quantification of lung luminescence indicated that all
CAFs caused a four-fold to seven-fold increase in total pulmonary
metastatic burden relative to tumor cells injected alone (Figure 6B and
Figure 5. RMFs and CAFs differentially modulate primary tumor growth. (A) Tumor growth curves of 231-Lux cells alone (green) or in
combination with RMFs (blue) or CAFs (red). Representative experiments performed with RMFs and CAFs isolated from three different
individuals each are shown. P values correspond to Student’s t test comparing growth curves in the presence of each fibroblast relative
to 231-Lux cells alone. Experiments with each RMF and CAF were performed at least twice. (B) Graph of fold change in final tumor volume
and weight in the presence of RMFs isolated from four different individuals (in blue from left to right: 163, 156, 9, 146) or CAFs isolated from
three different individuals (in red from left to right: 1366, 559, 1363) relative to the 231-Lux cells alone for all experiments combined. The
number of mice in each group and the P values comparing the effects of each RMF and CAF on tumor volume and weight relative to the
231-Lux cells alone are shown in Table 2.
Table 2. Summary of the Effect of Fibroblasts on Primary Tumor Formation.
Cells Injected Number of Mice Injected Number of Mice with Tumors Tumor Latency (Days) Final Tumor Volume (Fold Change) Final Tumor Weight (Fold Change)
231 Alone n = 63 62/63 22 ± 0.3
231 + RMF163 n = 10 10/10 26 ± 1.5 0.49 ± 0.03x (P < .001) 0.54 ± 0.04x (P < .001)
231 + RMF156 n = 8 8/8 22 ± 0.9 0.69 ± 0.04x (P < .001) 0.72 ± 0.05x (P < .001)
231 + RMF9 n = 5 4/5 28 ± 1.5 0.46 ± 0.07x (P < .001) 0.56 ± 0.09x (P = .002)
231 + RMF146 n = 6 6/6 27 ± 0.9 0.67 ± 0.08x (P = .002) 0.65 ± 0.05x (P < .001)
231 + CAF1366 n = 10 10/10 19 ± 0.4 1.04 ± 0.07x (P = .589) 1.15 ± 0.06x (P = .024)
231 + CAF559 n = 12 12/12 19 ± 0.5 1.34 ± 0.09x (P < .001) 1.29 ± 0.08x (P = .001)
231 + CAF1363 n = 17 17/17 25 ± 0.6 0.64 ± 0.04x (P < .001) 0.72 ± 0.05x (P < .001)
231-Lux cells were injected orthotopically either alone (5 × 105) or in combination with 1.5 × 106 fibroblasts, as indicated, and tumors were harvested 8 weeks following injection. P values correspond to
Student’s t test comparing the fold change in final tumor volume or weight ± SEM in the presence of each fibroblast relative to the 231-Lux cells alone.
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Table 3). Remarkably, even CAF1363, which caused a decrease in final
tumor weight and volume, increased both the number of surface lung
metastases (2.3-fold, P = .022) and total pulmonary metastatic burden
(6.9-fold, P = .015).
In light of these data, we wondered whether the primary tumors that
grew in the presence of CAF1363 might be smaller not because
CAF1363 inhibited their proliferation or survival, but rather because
it actively promoted their dissemination into the circulation. To address
this question, we 1) assessed the proliferative status of the primary
tumors by Ki67 staining and apoptotic cell death by CC3 staining,
2) examined whether the aligned ECM deposited by CAFs in vitro
could also be detected in vivo, and 3) collected blood 8 weeks following
injection of 231-Lux cells with or without CAF1363 to quantify the
number of CTCs. A group of mice injected with RMF146 was used
for comparison in these analyses. Quantification of Ki67 and CC3 stain-
ing indicated that CAF1363 did not inhibit the proliferation of tumors
nor did it promote apoptosis (Figure 7, A and B). In contrast, RMF146
promoted apoptosis but had no effect on proliferation. Picrosirius stain-
ing of the tumors indicated that aligned ECM could, in fact, be detected
in tumors that arose in the presence of CAF1363 and differed from the
sparser more randomly organized ECM present in tumors that arose
when the cells were injected alone or in the presence of RMF146 (Fig-
ure 7C), suggesting that the tumor cells could potentially use the aligned
ECM to migrate away from the tumors and into the circulation. Indeed,
CAF1363 caused a 2.1-fold increase in the number of CTCs relative to
the cells injected alone, while RMF146 caused a decrease in the number
of CTCs, but this decrease was not statistically significant (Figure 7D).
Collectively, these data suggest that the tumors that grew in the presence
of CAF1363 may be smaller due to increased dissemination facilitated
by the aligned ECM present in these tumors.
Consistent with these latter observations, immunoblot analysis of
ECM assembly proteins expressed in RMFs and CAFs revealed that,
relative to all the fibroblasts examined, CAF1363 secreted the highest
levels of 1) Fn, 2) biglycan, a matrix assembly protein whose targeted
disruption results in abnormal collagen fibril morphology [26], and 3)
LOX, an enzyme that plays a critical role in the cross-linking of ECM
proteins, the formation of invadopodia, migration, and metastasis [27]
(Figure 7E). Hence, given their role in ECM assembly and metastasis,
the high levels of biglycan and LOX expression in CAF1363 could
account for the increased dissemination and abundance of aligned
ECM present in the tumors that arose in the presence of CAF1363.
In addition to being most highly expressed in CAF1363, Fn, LOX,
as well as the matrix protein, TNC, were also more highly expressed
in the fibroblasts that induced the aligned mesenchymal phenotype
relative to those that did not. This was true not only for the CAFs
that induced the aligned mesenchymal phenotype but also for the
one RMF (referred to as RMF-Mes) that induced the mesenchymal
phenotype (Table 1 and Figures 7E and 8A).
Figure 6. RMFs suppress, while CAFs enhance, the metastatic po-
tential of malignant cells in vivo. Graphs of fold change in (A) the
number of metastatic foci per lung or (B) lung luminescence as a
measure of total pulmonary metastatic burden in the presence of
RMFs (in blue from left to right: 163, 156, 9, 146) or CAFs (in red from
left to right: 1366, 559, 1363) relative to the 231-Lux cells alone for all
experiments combined. The number of mice in each group and the
P values comparing the effects of each RMF and CAF on metastatic
burden relative to the 231-Lux cells alone are shown in Table 3.
Table 3. Summary of the Effect of Fibroblasts on Lung Metastasis.
Cells Injected Number of Mice Injected Number of Mice with
Lung Metastases
Number of Surface Metastases per Lung
(Fold Change over Control)
Amount of Lung Luminescence
(Fold Change over Control)
231 Alone n = 63 58 (92%)
231 + RMF163 n = 10 8 (80%) 0.43 ± 0.14x (P = .004) 0.69 ± 0.24x (P = .24)
231 + RMF156 n = 8 7 (88%) 1.73 ± 0.46x (P = .157) 3.62 ± 1.18x (P = .06)
231 + RMF9 n = 5 3 (60%) 0.60 ± 0.29x (P = .239) 1.15 ± 0.66x (P = .83)
231 + RMF146 n = 6 6 (100%) 0.30 ± 0.10x (P = .006) 0.47 ± 0.12x (P = .007)
231 + CAF1366 n = 10 10 (100%) 1.95 ± 0.35x (P = .024) 7.77 ± 1.99x (P = .008)
231 + CAF559 n = 12 11 (92%) 3.46 ± 0.87x (P = .016) 4.11 ± 1.56x (P = .07)
231 + CAF1363 n = 17 16 (94%) 2.29 ± 0.51x (P = .022) 6.90 ± 2.17x (P = .015)
231-Lux cells were injected orthotopically either alone (5 × 105) or in combination with 1.5 × 106 fibroblasts, as indicated, and lungs were harvested for analysis 8 weeks following injection. P values
correspond to the results of Student’s t test comparing the fold change in the number of metastatic foci per lung ± SEM in the presence of each fibroblast relative to the 231-Lux cells alone as well as the
fold change in lung luminescence ± SEM as a measure of total pulmonary metastatic burden in the presence of each fibroblast relative to the 231-Lux cells alone.
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An RMF that Induces an Aligned Mesenchymal Phenotype
Can Enhance Dissemination but Not Metastasis
Having observed that CAFs that can induce an aligned mesenchymal
phenotype in vitro could promote the dissemination and metastasis of
tumor cells in vivo, we then examined whether an RMF that induced an
alignedmesenchymal phenotype in vitro (Figure 8A) could also promote
dissemination and metastasis. To address this question, 231-Lux cells
were injected orthotopically either alone or in combination with
RMF-Mes. Eight weeks following injection, blood was collected for
the quantification of CTCs, and lungs were harvested for the quan-
tification of surface metastases and lung bioluminescence. In these
experiments, RMF-Mes enhanced the dissemination of 231-Lux cells
Figure 7. CAFs deposit aligned matrix and promote dissemination of malignant cells in vivo. Representative 20× images of tumors stained
with (A) Ki67, (B) CC3, or (C) picrosirius, grown in the absence (alone) or presence of RMF146 or CAF1363, as indicated. Staining was quan-
tified using three to four randomly chosen fields from each tumor section. Alone (n= 34, 15, 10), RMF146 (n= 12, 8, 8), and CAF1363 (n=
22, 12, 7) for stains shown in A, B, and C, respectively. Quantification of stains is shown in bar graphs as average ± SEM for each group.
P values correspond to Student’s t test comparing scores of tumors grown in the presence or absence of fibroblasts. For Ki67: alone
versus RMF146 (P = .11), alone versus CAF1363 (P = .72); for CC3: alone versus RMF146 (P < .001), alone versus CAF1363 (P = .8); for
ECM abundance: alone versus RMF146 (P = .09), alone versus CAF1363 (P < .001); for ECM alignment: alone versus RMF146 (P = .04),
alone versus CAF1363 (P < .001). (D) qPCR analysis of EpCAM levels in genomic DNA extracted from blood collected 8 weeks following
injection of 5 × 105 231-Lux cells alone (n = 9) or in combination with 1.5 × 106 RMF146 (n = 4), or 1.5 × 106 CAF1363 (n = 7). Student’s
t test comparing qPCR replicates from alone versus RMF146 (P= .15), alone versus CAF1363 (P= .04), and RMF146 versus CAF1363 (P= .01).
(E) Representative immunoblotsof Fn, TNC, biglycan, andLOXexpression inMDA-MB-231cells (231),RMFs (163, 156, 009, 146,Mes), andCAFs
(1366, 559, 1363). “Mes” denotes an RMF that induced the aligned mesenchymal phenotype. Statistically significant differences between end-
points measured in tumors grown alone versus with fibroblasts are denoted with asterisk.
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as evidenced by the detection of a 3.8-fold higher number of CTCs
in the blood of mice injected with RMF-Mes relative to those injected
with 231-Lux cells alone (Figure 8B). However, the presence of RMF-
Mes did not increase the number of surface metastases per lung or
total pulmonary metastatic burden (Figure 8, C and D). These data
indicate that the induction of an aligned mesenchymal phenotype
alone is sufficient to promote early dissemination but not sufficient to
enhance the formation of overt metastases.
Discussion
In this report, we have shown that both premalignant (vHMEC-
ras0.5) and malignant (MDA-MB-231) mammary epithelial cells
can assume an aligned mesenchymal morphology when co-cultured
with CAFs but not RMFs. This phenotype differs from the classic
epithelial-to-mesenchymal transition that is accompanied by a down-
regulation of E-cadherin. Instead, this mesenchymal phenotype appears
to be governed at least in part by the organization of the ECM de-
posited by CAFs in that it was not induced by CAF-conditioned media
or CAFs in transwell co-cultures with the epithelial cells where the two
cell populations were not in contact with one another, but it was in-
duced when the epithelial cells were overlaid on top of ECM deposited
by CAFs, and it was blocked in co-cultures when deposition of ECM
was blocked. Thus, while it is well known that some CAF-induced phe-
notypes can be transmitted by secreted factors [24], this particular CAF-
induced phenotype requires contact with deposited ECM proteins.
Importantly, our data indicate that the phenotype induced by CAFs
in vitro is biologically relevant in vivo in that the aligned ECM de-
posited by CAFs in vitro could be detected in the mammary glands
of mice following co-injection with premalignant cells as well as in
tumors following co-injection with malignant cells. This ECM pheno-
type is also clinically relevant in that studies have shown that the radial
alignment of collagen fibers relative to tumors facilitates local invasion
[15], and correlates with poor disease-free survival, suggesting that
quantifying collagen alignment could be a viable, novel strategy for
the prediction of human breast cancer survival [16]. Our results re-
inforce this notion and, in addition, suggest that the presence of
aligned collagen could also predict dissemination in the earliest stages
of breast cancer development.
There is increasing evidence that in some cancers, tumor cells start
spreading long before the primary tumor is detected and removed
[2,28]. Our data suggest that alterations in the composition and
organization of the ECM surrounding premalignant lesions could
account for this. Alterations in the ECM component of the stroma that
resemble those observed in malignant lesions are often observed in the
context of wound healing, radiation response, pregnancy-associated
involution, and high mammographic density [29–33]. These altera-
tions manifest even in the absence of malignancy and may thus pro-
vide a favorable environment for early dissemination of premalignant
cells. This might explain why certain cancers that are driven by alter-
ations in ECM, such as postpartum breast cancers, have such poor
prognosis [32] and why metastatic dissemination can occur in women
with small tumors.
Our data suggest that alterations in stromal ECM that result in the
induction of an aligned mesenchymal phenotype are both necessary
and sufficient to enhance dissemination because a CAF that failed to
Figure 8. Induction of the aligned mesenchymal phenotype by an RMF enhances dissemination but is not sufficient to promote metastasis.
(A) Representative 10× images of ras0.5-GFPLux and 231-Lux cells cultured in the absence (alone) or presence of RMF-Mes (+RMF-Mes)
for 3 days. (B) qPCR analysis of EpCAM levels in genomic DNA extracted from blood shown as average ± SEM. (C) Graph depicting the average
number of surface metastases per lung ± SEM. (D) Graph depicting the quantification of lung luminescence ± SEM as a measure of total
metastatic burden. All measurements shown in B to D were taken 8 weeks following injection of 5 × 105 231-Lux cells alone (n = 17) or
in combination with 1.5 × 106 RMF-Mes (n = 12). Student’s t test comparing results obtained in the presence of RMF-Mes relative to
the 231-Lux cells alone (CTCs, P = .007; surface metastases, P = .8; total metastatic burden, P = .9). Statistically significant difference is
denoted with asterisk.
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induce the phenotype did not enhance dissemination (Figure W8) and
an RMF that did induce the mesenchymal phenotype did (Figure 8).
However, unlike the induction of the aligned mesenchymal phenotype
by a CAF, which enhanced both dissemination and metastasis, the
aligned mesenchymal phenotype induced by an RMF enhanced dis-
semination but not metastasis. These data indicate that reorganization
of the ECM plays a key role in the early stages of the metastatic cas-
cade but is not sufficient to bestow on tumor cells a fully enhanced
metastatic potential and suggest that CAFs induce additional altera-
tions in tumor cells that endow them with the ability to metastasize
more efficiently. Notably, the alterations that drive metastatic dis-
semination are uncoupled from those that drive primary tumor growth
as all three CAFs co-injected with tumor cells increased pulmonary
metastatic burden (Figure 6 and Table 3) whether they stimulated,
inhibited, or failed to affect primary tumor growth (Figure 5 and
Table 2). These data highlight the heterogeneity of signals emanating
from the tumor microenvironment.
Importantly, the composition and organization of the ECM cannot
only promote the tumorigenic and metastatic potential of malignant
cells, but it can also constrain it, as RMFs isolated from four different
disease-free individuals inhibited primary tumor growth (Figure 5
and Table 2) and one of these also inhibited metastatic spread to the
lung (Figure 6 and Table 3). In addition, RMFs also inhibited the dis-
semination of premalignant cells (Figure 4). These data imply that
maintaining a normal ECM environment can be therapeutically bene-
ficial. Along these lines, others have shown that normalizing a matrix-
rich desmoplastic stroma can enhance the delivery and efficacy of
chemotherapy [34,35]. In one study, this was achieved with the anti-
hypertensive drug losartan, which depletes ECM in part by suppressing
active TGFβ levels [35,36]. Consistent with this, we observed that
blocking TGFβ signaling as well as other signaling pathways through
which TGFβ induces a mesenchymal phenotype and ECM remodeling
prevented the CAF-induced mesenchymal phenotype in co-culture
assays. TGFβ’s role in promoting metastasis is well established; how-
ever, targeting TGFβ in the clinic has been a challenge due to the com-
plex nature of TGFβ’s tumor suppressive and tumor promoting actions.
Losartan may represent a safe alternative to indirectly inhibit some of
the ECM-related pro-metastatic effects of TGFβ. In fact, losartan has
been used clinically to abrogate excess TGFβ in patients with Marfan’s
syndrome, a genetic disorder caused by mutations in the ECM protein
fibrillin-1, which binds to the large latent TGFβ complex [37,38]. Anti-
hypertensive therapeutics such as losartan could potentially also be used
prophylactically, as there is evidence that women on anti-hypertensive
therapy have a lower risk of developing breast cancer [39].
In conclusion, our data underscore the potential of the ECM as a
prognostic and therapeutic target. Targeting ECM proteins, such as
biglycan and LOX, that are involved in the organization and cross-
linking of collagen may prove effective in limiting dissemination, an
event that may occur much earlier than previously appreciated. Hence,
the possibility that cells may have disseminated long before the de-
tection of the primary tumor must be considered when designing
experiments and testing new therapeutics. To make personalized cancer
medicine a success, companion diagnostics aimed at identifying the
right patient populations for the right therapeutics should also include
markers to assess early systemic cancer spread.
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Supplementary Materials
Quantification of Regularity Index
This section summarizes the computational protocol for captur-
ing intrinsic geometric patterns in collagen formation for treatment
groups. Toward this goal, we derived two indices corresponding to
the amount of collagen and its regularity in each sample because both
of these indices can be associated to invasive properties. The main
challenge is quantifying the regularity index, because 1) there could
be multiple collagen bundles in a sample, 2) collagen bundles are
often perceptual and lack continuity as a result of either sample
preparation or microscopy, and 3) each bundle may have a different
density and/or strength. Therefore, we have designed a protocol with
filters that 1) fill perceptual gaps, 2) compute regularity locally,
through steerable filters, and then aggregate the local filter responses
over the entire image, and 3) are rotationally invariant so that the
fiber bundles in orthogonal directions remain additive. The details
of these computational steps can be found in our earlier publications
and those of others. The protocol is a cascade of operators, shown in
Figure W2, and consists of:
1. Converting the original image from RGB space to grayscale
space. This step simplifies 1) the collagen content into one
dimension and 2) the application of steerable filters for local
feature extraction.
2. Detecting collagen signals through Otsu thresholding [1]. This
step differentiates the signal (foreground) from the background,
and it enables the computation of percentage of collagen content
per image and per treatment group.
3. Applying perceptual grouping and regularization through tan-
gential voting [2], where voting is only applied to the thre-
sholded foreground pixels. As a result, only the foreground
pixels can cast their information (e.g., orientation) into a local
neighborhood. The net result is a more regularized structure,
where small gaps are filled.
4. Calculating the regularity index for each foreground pixel from
the responses from the steerable filter bank [2], where the filters
are oriented (e.g., having an ellipsoidal shape) as first or second
derivatives of Gaussians. The regularity index, RI for a pixel, p,
is defined as follows:
RIðpÞ = stdfMSFRθ1N ðpÞ;MSFRθ2N ðpÞ;
…;MSFRθiN ðpÞ;…;MSFRθkN ðpÞg;
ð1Þ
where std{…} corresponds to the standard deviation of the local
responses; MSFRN
θi(p) is the mean steerable filter response along
orientation θi, for pixel p, within a local neighborhood of N ; and
k is the total number of orientations for the steerable filter bank.
The rationale for this design index is that random (irregular) struc-
tures do not have preferred orientation, which leads to relatively
invariant filter responses among different orientations; thus, the
regularity index is low. This concept is demonstrated in FigureW3.
5. Calculating the regularity composition index per image, where
regular and irregular structures are differentiated through a sim-
ple thresholding policy. The threshold, T , is determined empir-
ically by learning from the spatial distribution of the fiber
bundles. In addition, the regularity composition index is simply
the percentage of regular signals in an image, e.g.,
Regularity Composition = Regular Signal=All Signal: ð2Þ
Having validated our approach on synthetic images, we then apply
our approach on the real data. The parameter settings were kept
constant for all experimental factors.
Local neighborhood: N = 300 by 300 pixels;
Number of orientations: k = 16;
Scale for steerable filter: σ = 6.0;
Threshold for regularity: T = 600.
Several examples are shown in Figure W4.
[1] Otsu N (1979). A threshold selection method from gray-level histograms. IEEE
Trans Syst Man Cyber 9(1), 62–66.
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(2010). Multidimensional profiling of cell surface proteins and nuclear markers.
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Figure W2. The workflow for quantification of regularity on a synthetic image: (A) the grayscale image converted from RGB space;
(B) signal is thresholded and the percentage of collagen is computed per image; (C) perceptual gaps are filled through tangential voting;
and (D) an index for each pixel that correlates with regularity in pattern formation is computed.
Figure W3. Construction of the regularity index on a synthetic image computed with four orientations of a steerable filter bank: (A) a
synthetic image with regular and irregular fibers, where two points (red and yellow) are selected; (B) mean steerable filter responses at
each of the four orientations for the red point; and (C) mean steerable filter responses for each of the four orientations for the yellow
point. These examples show that a regular structure has much larger variance of steerable filter responses along different orientations
than an irregular structure.
Figure W1. qPCR analysis of EpCAM levels in genomic DNA
extracted from blood collected from naïve mice that was spiked
with increasing numbers of human 231-Lux cells, as indicated. Bar
graphs represent the averages ± SEM of replicates in a represen-
tative experiment.
Figure W4. Examples of the quantification of the regularity composition index on a pair of real data. First row (top): The grayscale
images converted from RGB space. Second row: Thresholded signal where the percentage of collagen is also computed. Third row:
As a result of tangential voting, thresholded signal becomes more continuous and small gaps are filled. Fourth row: Computed regularity
index for each pixel indicates that the image on the left has a higher regularity composition index.
Figure W5. Representative 10× images of vHMEC-ras0.5 cells cultured alone or in combination with fibroblasts for 3 days (top row), and
after they were isolated from the co-cultures and replated on their own in the absence of fibroblasts (bottom row) demonstrating that
continued exposure to CAFs, or the ECM they deposit, is required for the maintenance of the aligned mesenchymal phenotype.
Figure W6. Flow cytometric analysis of Thy-1 expression in vHMEC-
ras0.5 cells cultured either alone orwith fibroblasts in the absence or
presence of the TβRKi demonstrating that blockade of the CAF-
inducedmesenchymal phenotype is associatedwith a corresponding
decrease in Thy-1 expression.
Figure W7. Higher magnification images of the H&E, lamin, and picrosirius stains shown in Figure 4.
Figure W8. (A) Representative 10× images of vHMEC-ras0.5 cells cultured alone or with CAF304 for 3 days. (B) qPCR analysis of EpCAM
levels in genomic DNA extracted from blood collected 2 and 5 weeks following orthotopic injection of 1 × 106 ras0.5-GFPLux cells alone
(n= 6) or in combination with 3 × 106 CAF304 (n= 6). Blood was collected from three mice at each time point. Bar graphs represent the
averages ± SEM of replicates in each experiment.
Figure W9. Representative 10× images of MDA-MB-231 cells co-cultured with RMFs or CAFs for 3 days.
Figure W11. Representative images of (A) organs subjected to bioluminescence imaging ex vivo to quantify metastatic burden, (B) whole
lung fixed in Bouin’s for enumeration of surface metastases, and (C) H&E-stained lung section confirming the presence of pulmonary
metastases. Arrows point to examples of metastatic nodules.
Figure W10. qPCR analysis of SDF-1 mRNA expression in RMFs
and CAFs indicating that SDF-1 is only elevated in CAF559, which
is the only CAF that stimulated primary tumor growth.
